Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue growth accelerates

Q3 FY2026 cost of revenue of $48.03M rose 24.8% year over year, ahead of the +0.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 10.2% from the prior quarter.

Context

  • Cost of revenue amounted to 65.7% of revenue in FY2025, down 9.9 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +24.8% holds above the trailing-twelve-month pace of +0.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$48.03M+10.2% QoQ
Last fiscal yearDec 2025
$173.18M+39.7% YoY
LTMSep 2026
$177.23M+0.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.8%——
1 year+39.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
173.18M USD
Year-over-year change
+39.7%

Cost of Revenue vs competitors

How IOVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.9% is the 5th highest of 9, against a peer median of +0.3%.
  • Cost of revenue amounts to 46.8% of revenue for IOVA, versus a peer median of 29.2%.
IOVA Competitors
Cost of Revenue for IOVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€771.34M EUR+32.4%-41.0%29.2%
LEGNLegend Biotech CorporationLTM Sep 2026$584.36M USD+63.0%+84.1%43.0%
GMABGenmab A/SLTM Jun 2026$288M USD——7.0%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$177.23M USD+0.9%—46.8%
FATEFate Therapeutics, Inc.LTM Mar 2026$32.58M USD-62.0%-2.1%515.8%
IBRXImmunityBio, Inc.LTM Sep 2026$6.07M USD+40.5%—3.3%
IMCRImmunocore Holdings plcLTM Mar 2026$4.61M USD+39.0%+5.5%1.2%
STTKShattuck Labs, Inc.LTM Mar 2026$1.82M USD-36.2%—182.0%
REPLReplimune Group, Inc.LTM Dec 2025$848K USD———
IMNMImmunome, Inc.LTM Sep 2026$753K USD-98.5%——
ALXOALX Oncology Holdings Inc.LTM Mar 2026$150K USD-31.8%——
Peer median (excluding IOVA) —+0.3%+1.7%29.2%

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.19M164.07M263.5M
Cost of Revenue0010.76M124M173.18M
Gross Profit00(9.57M)40.08M90.32M
Gross Margin——-804.5%24.4%34.3%
Research & Development259.04M294.78M344.08M282.34M300.27M
Selling, General & Admin83.66M104.1M106.92M153.02M152.32M
Operating Expenses342.7M398.88M450.99M435.35M488.53M
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
EBITDA(328.27M)(371.77M)(414.39M)(331.4M)(350.89M)
EBITDA Margin——-34851.9%-202.0%-133.2%
Operating Income(342.7M)(398.88M)(460.56M)(395.28M)(398.21M)
Operating Margin——-38735.0%-240.9%-151.1%
Interest Income451K2.99M13.04M20.27M10.31M
Interest Expense02.99M000
Other Income / Expenses451K2.99M13.04M20.27M5.16M
Income Before Tax(342.25M)(395.89M)(447.52M)(375.01M)(393.05M)
Pre-Tax Margin——-37638.0%-228.6%-149.2%
Income Tax Expense00(3.48M)(2.83M)(2.07M)
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Net Margin——-37345.4%-226.8%-148.4%
EPS (Basic)(2.23)(2.49)(1.89)(1.28)(1.09)
EPS (Diluted)(2.23)(2.49)(1.89)(1.28)(1.09)
Weighted Avg Shares153.41M159.26M235.13M289.88M357.35M
Weighted Avg Shares (Diluted)153.41M159.26M235.13M289.88M357.35M

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.